Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience
D A Ezeife1, B Melosky2, R Tudor3,4
1Princess Margaret Cancer Centre, University Health Network, Toronto, ON.
Background:
Afatinib, an irreversible epidermal growth factor receptor tyrosine kinase inhibitor (egfr tki), is approved for first-line therapy in advanced EGFR mutation-positive non-small-cell lung cancer (nsclc) and has previously demonstrated activity after failure of chemotherapy and reversible egfr tkis, with improved response and progression-free survival, compared with placebo. Outcomes in pretreated patients with advanced nsclc receiving afatinib through a Canadian special access program (sap) are reported here.
Methods:
Patients with nsclc progressing after at least 1 line of chemotherapy and an egfr tki were eligible to enrol in the sap. Characteristics of patients from the two largest accruing Canadian centres were retrospectively reviewed, including demographics, disease and treatment data, and patient outcomes.
Results:
The 53 patients who received afatinib (57% women, 51% never-smokers, 26% of East Asian ethnicity, and 66% with adenocarcinoma) had a median age of 59 years. EGFR mutations were documented in 25%, and EGFR wild-type in 8%. All patients had received prior egfr tki treatment, with 42% achieving a response. Patients took afatinib for a median of 2 months (range: 0-26 months); 17% required 1 or more dose reductions. Of 47 evaluable patients receiving afatinib, 10 experienced tumour shrinkage, and 11, stable disease. Median survival from afatinib initiation was 5 months (95% confidence interval: 2 months to 8 months). Grade 3 or greater diarrhea, rash, paronychia, and stomatitis were seen in 9%, 11%, 6%, and 4% of patients respectively.
Conclusions:
In an unselected population of pretreated patients with advanced nsclc after tki failure, median survival with afatinib therapy was 5 months. Through a sap, afatinib demonstrated activity in clinical practice, with manageable toxicity.
Insights
Afatinib showed activity in advanced non-small-cell lung cancer (NSCLC) patients previously treated with chemotherapy and EGFR TKIs. This real-world study found a median survival of 5 months with manageable side effects.
Area of Science:
- Oncology
- Pharmacology
Background:
- Afatinib is an irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) approved for advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).
- Afatinib has demonstrated efficacy after chemotherapy and reversible EGFR TKI failure.
Purpose of the Study:
- To report outcomes of pretreated advanced NSCLC patients receiving afatinib through a Canadian special access program (SAP).
Main Methods:
- Retrospective review of patient data from two Canadian centers.
- Inclusion criteria: NSCLC patients progressing after at least one line of chemotherapy and an EGFR TKI.
Main Results:
- 53 patients received afatinib; median age 59, 66% adenocarcinoma. 25% had documented EGFR mutations, 8% EGFR wild-type.
- Median survival from afatinib initiation was 5 months. 10 patients experienced tumor shrinkage, 11 had stable disease.
- Grade 3+ toxicities included diarrhea (9%), rash (11%), paronychia (6%), and stomatitis (4%).
Conclusions:
- Afatinib demonstrated activity in an unselected population of pretreated advanced NSCLC patients after TKI failure.
- Real-world data from a SAP indicates afatinib has manageable toxicity in clinical practice.
Related Concept Videos
01:47Lung Capacity
01:12What is an Experiment?
02:22Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
03:20The Stanford Prison Experiment
00:56Extraction: Advanced Methods
01:19Thomson's e/m Experiment
A particle with charge q, speed v, and mass m enters an area from the top, where the magnetic and electric fields are perpendicular both to the particle's motion and to one another. The magnetic...